Oyster Point Pharma, Inc. clinical trials
Acquired by Viatris Inc., Jan 3, 2023 · source ↗
The registry lists 11 studies whose lead sponsor is Oyster Point Pharma, Inc.. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated May 6, 2025.
Before and after it joined Viatris Inc.
- First submitted before Oyster Point Pharma, Inc. became part of Viatris Inc.
- 9
- First submitted after Oyster Point Pharma, Inc. became part of Viatris Inc.
- 2
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
Registry sponsor names on this page
- Oyster Point Pharma, Inc.11 studies
Something wrong with this grouping? Tell us on the Viatris Inc. page.
Studies
Recruiting first, then most recently updated. Showing 11 of 11. All Viatris Inc. studies →
- Phase 4 Study Evaluating the Safety of the Nasal Guide With TyrvayaCompletedNCT05918406Phase 4
Sponsor listed in the registry: Oyster Point Pharma, Inc. · First submitted after Oyster Point Pharma, Inc. became part of Viatris Inc.
- A Study Evaluating the Safety of the Nasal PumpTerminatedNCT06329687Phase 4
Sponsor listed in the registry: Oyster Point Pharma, Inc. · First submitted after Oyster Point Pharma, Inc. became part of Viatris Inc.
- Phase 2 Clinical Trial to Evaluate OC-01 Nasal Spray in Subjects With Neurotrophic KeratopathyCompletedNCT04957758Phase 2
Sponsor listed in the registry: Oyster Point Pharma, Inc. · First submitted before Oyster Point Pharma, Inc. became part of Viatris Inc.
- Evaluation of the Long Term Follow up of the Efficacy of OC-01 Nasal Spray on Signs and Symptoms of Dry Eye DiseaseCompletedNCT03920215Phase 2/3
Sponsor listed in the registry: Oyster Point Pharma, Inc. · First submitted before Oyster Point Pharma, Inc. became part of Viatris Inc.
- Clinical Trial to Evaluate the Chronic Efficacy of OC-01 Nasal Spray on Signs of Dry Eye Disease (The MYSTIC Study)CompletedNCT03873246Phase 2
Sponsor listed in the registry: Oyster Point Pharma, Inc. · First submitted before Oyster Point Pharma, Inc. became part of Viatris Inc.
- Evaluating Relative Bioavailability of OC-01 (Varenicline) Nasal Spray as Compared to Orally Administered VareniclineCompletedNCT04072146Phase 1
Sponsor listed in the registry: Oyster Point Pharma, Inc. · First submitted before Oyster Point Pharma, Inc. became part of Viatris Inc.
- Evaluation of the Efficacy of OC-02 Nasal Spray on Signs and Symptoms of Dry Eye Disease (the RAINIER Study)CompletedNCT03633461Phase 2
Sponsor listed in the registry: Oyster Point Pharma, Inc. · First submitted before Oyster Point Pharma, Inc. became part of Viatris Inc.
- Efficacy of OC-01 Nasal Spray on Goblet Cell and Meibomian Gland StimulationCompletedNCT03688802Phase 2
Sponsor listed in the registry: Oyster Point Pharma, Inc. · First submitted before Oyster Point Pharma, Inc. became part of Viatris Inc.
- Clinical Trial to Evaluate the Efficacy of OC-02 Nasal Spray on Signs and Symptoms of Dry Eye Disease (The PEARL Study)CompletedNCT03452397Phase 2
Sponsor listed in the registry: Oyster Point Pharma, Inc. · First submitted before Oyster Point Pharma, Inc. became part of Viatris Inc.
- Evaluation of the Efficacy and Safety of OC-01 Nasal Spray on Signs and Symptoms of Dry Eye DiseaseCompletedNCT04036292Phase 3
Sponsor listed in the registry: Oyster Point Pharma, Inc. · First submitted before Oyster Point Pharma, Inc. became part of Viatris Inc.
- Evaluation of the Efficacy of OC-01 Nasal Spray on Signs and Symptoms of Dry Eye DiseaseCompletedNCT03636061Phase 2
Sponsor listed in the registry: Oyster Point Pharma, Inc. · First submitted before Oyster Point Pharma, Inc. became part of Viatris Inc.